Skip to content
2000
image of Diagnostic Value of Galactomannan Enzyme Immunoassay Compared to Conventional Modalities in Bronchoalveolar Lavage of Immunocompromised Patients

Abstract

Introduction

is the leading cause of Invasive Aspergillosis (IA) worldwide. Diagnosing IA can be challenging due to difficulties in sample collection and the limited sensitivity and specificity of culture-based methods, often leading to delayed diagnosis and increased morbidity. Galactomannan (GM) testing, an antigen released by during infection, offers a valuable alternative. Detection of GM, along with other diagnostic criteria, can facilitate quicker identification of IA, reducing turnaround times and improving patient management.

Methods

A prospective study was conducted over four months in the Mycology Laboratory of a tertiary care hospital in Delhi. A total of 45 Bronchoalveolar Lavage (BAL) samples were collected from immunocompromised patients at the Delhi State Cancer Institute. Conventional diagnostic methods, including Gram staining, KOH mount, India ink staining, and culture, were performed, along with the XEMA GalMAg EIA for the detection of GM antigen. The results obtained were compared and analyzed.

Results

GM was detected in 4 out of 45 samples (8.88%), while 3 other samples yielded equivocal results in the ELISA. Of these seven samples, three demonstrated bacterial and yeast growth in culture, with findings consistent with Gram stain results. We found that 6.7% (3/45) of patients had a history of chemotherapy, 8.9% (4/45) presented with respiratory symptoms, and 8.9% (4/45) exhibited systemic signs. CT scan findings showed multiple nodular lesions in the lung fields in 8.9% (4/45) of cases. Lymphocytopenia was observed in the absence of neutropenia.

Discussion

Detecting GM antigen in BAL samples may help in the early diagnosis of IA in cancer patients, especially those undergoing chemotherapy. Although GM testing showed limited positive results in this small group, it can still be a useful tool when combined with clinical and radiological findings, but further follow-up and confirmatory tests are needed to improve diagnostic accuracy.

Conclusion

The detection of GM, along with other clinical and radiological findings, aids in the early identification of IA, potentially improving patient outcomes by reducing diagnostic delays.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crmr/10.2174/011573398X390376251016161929
2026-01-22
2026-02-04

  • From This Site

    /content/journals/crmr/10.2174/011573398X390376251016161929
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Epidemiology and clinical manifestations of invasive aspergillosis. Available from: https://www.uptodate.com/contents/epidemiology-and-clinical-manifestations-of-invasive-aspergillosis. 2025.
  2. Bassetti M. Azoulay E. Kullberg B.J. Ruhnke M. Shoham S. Vazquez J. Giacobbe D.R. Calandra T. EORTC/MSGERC definitions of invasive fungal diseases: Summary of activities of the intensive care unit working group. Clin Infect Dis 2021 72 Suppl. 2 S121 S127 10.1093/cid/ciaa1751 33709127
    [Google Scholar]
  3. Huppler A.R. Fisher B.T. Lehrnbecher T. Walsh T.J. Steinbach W.J. Role of molecular biomarkers in the diagnosis of invasive fungal diseases in children. J Pediatric Infect Dis Soc 2017 6 Suppl. 1 S32 S44 10.1093/jpids/pix054 28927202
    [Google Scholar]
  4. Mercier T. Guldentops E. Lagrou K. Maertens J. Galactomannan, a surrogate marker for outcome in invasive aspergillosis: Finally coming of age. Front Microbiol 2018 9 661 10.3389/fmicb.2018.00661 29670608
    [Google Scholar]
  5. Zhou W. Li H. Zhang Y. Huang M. He Q. Li P. Zhang F. Shi Y. Su X. Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fluid samples from patients with nonneutropenic invasive pulmonary aspergillosis. J Clin Microbiol 2017 55 7 2153 2161 10.1128/JCM.00345‑17 28446576
    [Google Scholar]
  6. Patterson T.F. Thompson G.R. Denning D.W. Fishman J.A. Hadley S. Herbrecht R. Kontoyiannis D.P. Marr K.A. Morrison V.A. Nguyen M.H. Segal B.H. Steinbach W.J. Stevens D.A. Walsh T.J. Wingard J.R. Young J.A.H. Bennett J.E. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of america. Clin Infect Dis 2016 63 4 e1 e60 10.1093/cid/ciw326 27365388
    [Google Scholar]
  7. Donnelly J.P. Chen S.C. Kauffman C.A. Steinbach W.J. Baddley J.W. Verweij P.E. Clancy C.J. Wingard J.R. Lockhart S.R. Groll A.H. Sorrell T.C. Bassetti M. Akan H. Alexander B.D. Andes D. Azoulay E. Bialek R. Bradsher R.W. Bretagne S. Calandra T. Caliendo A.M. Castagnola E. Cruciani M. Cuenca-Estrella M. Decker C.F. Desai S.R. Fisher B. Harrison T. Heussel C.P. Jensen H.E. Kibbler C.C. Kontoyiannis D.P. Kullberg B-J. Lagrou K. Lamoth F. Lehrnbecher T. Loeffler J. Lortholary O. Maertens J. Marchetti O. Marr K.A. Masur H. Meis J.F. Morrisey C.O. Nucci M. Ostrosky-Zeichner L. Pagano L. Patterson T.F. Perfect J.R. Racil Z. Roilides E. Ruhnke M. Prokop C.S. Shoham S. Slavin M.A. Stevens D.A. Thompson G.R. Vazquez J.A. Viscoli C. Walsh T.J. Warris A. Wheat L.J. White P.L. Zaoutis T.E. Pappas P.G. Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis 2020 71 6 1367 1376 10.1093/cid/ciz1008
    [Google Scholar]
  8. Affolter K. Tamm M. Jahn K. Halter J. Passweg J. Hirsch H.H. Stolz D. Galactomannan in bronchoalveolar lavage for diagnosing invasive fungal disease. Am J Respir Crit Care Med 2014 190 3 309 317 10.1164/rccm.201403‑0431OC 25007380
    [Google Scholar]
  9. Clancy C.J. Jaber R.A. Leather H.L. Wingard J.R. Staley B. Wheat L.J. Cline C.L. Rand K.H. Schain D. Baz M. Nguyen M.H. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007 45 6 1759 1765 10.1128/JCM.00077‑07 17428933
    [Google Scholar]
  10. Husain S. Paterson D.L. Studer S.M. Crespo M. Pilewski J. Durkin M. Wheat J.L. Johnson B. McLaughlin L. Bentsen C. McCurry K.R. Singh N. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007 83 10 1330 1336 10.1097/01.tp.0000263992.41003.33 17519782
    [Google Scholar]
  11. Maertens J. Maertens V. Theunissen K. Meersseman W. Meersseman P. Meers S. Verbeken E. Verhoef G. Van Eldere J. Lagrou K. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 2009 49 11 1688 1693 10.1086/647935 19886801
    [Google Scholar]
  12. Desai R. Ross L.A. Hoffman J.A. The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis. Pediatr Infect Dis J 2009 28 4 283 286 10.1097/INF.0b013e31818f0934 19238113
    [Google Scholar]
  13. Becker M.J. Lugtenburg E.J. Cornelissen J.J. Van Der Schee C. Hoogsteden H.C. De Marie S. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003 121 3 448 457 10.1046/j.1365‑2141.2003.04308.x 12716367
    [Google Scholar]
  14. Musher B. Fredricks D. Leisenring W. Balajee S.A. Smith C. Marr K.A. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004 42 12 5517 5522 10.1128/JCM.42.12.5517‑5522.2004 15583275
    [Google Scholar]
  15. Bergeron A. Belle A. Sulahian A. Lacroix C. Chevret S. Raffoux E. Arnulf B. Socié G. Ribaud P. Tazi A. Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Chest 2010 137 2 410 415 10.1378/chest.09‑0701 19801584
    [Google Scholar]
  16. Bassetti M. Giacobbe D.R. Agvald-Ohman C. Akova M. Alastruey-Izquierdo A. Arikan-Akdagli S. Azoulay E. Blot S. Cornely O.A. Cuenca-Estrella M. de Lange D.W. De Rosa F.G. De Waele J.J. Dimopoulos G. Garnacho-Montero J. Hoenigl M. Kanj S.S. Koehler P. Kullberg B.J. Lamoth F. Lass-Flörl C. Maertens J. Martin-Loeches I. Muñoz P. Poulakou G. Rello J. Sanguinetti M. Taccone F.S. Timsit J.F. Torres A. Vazquez J.A. Wauters J. Asperges E. Cortegiani A. Grecchi C. Karaiskos I. Le Bihan C. Mercier T. Mortensen K.L. Peghin M. Rebuffi C. Tejada S. Vena A. Zuccaro V. Scudeller L. Calandra T. Roger C. Eckmann C. Gangneux J-P. Segal E. Coombs G. Voss A. Invasive fungal diseases in adult patients in intensive care unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM. Intensive Care Med 2024 50 4 502 515 10.1007/s00134‑024‑07341‑7 38512399
    [Google Scholar]
  17. Koulenti D. Papathanakos G. Blot S. Invasive pulmonary aspergillosis in the ICU: Tale of a broadening risk profile. Curr Opin Crit Care 2023 29 5 463 469 10.1097/MCC.0000000000001070 37641513
    [Google Scholar]
  18. Cai X. Ni W. Wei C. Cui J. Diagnostic value of the serum galactomannan and (1, 3)-β-D-glucan assays for invasive pulmonary aspergillosis in non-neutropenic patients. Intern Med 2014 53 21 2433 2437 10.2169/internalmedicine.53.2381 25366000
    [Google Scholar]
  19. Dobias R. Jaworska P. Tomaskova H. Kanova M. Lyskova P. Vrba Z. Holub C. Svobodová L. Hamal P. Raska M. Diagnostic value of serum galactomannan, (1,3)-β- d -glucan, and Aspergillus fumigatus -specific IgA and IgG assays for invasive pulmonary aspergillosis in non-neutropenic patients. Mycoses 2018 61 8 576 586 10.1111/myc.12765 29575150
    [Google Scholar]
  20. Ullmann A.J. Aguado J.M. Arikan-Akdagli S. Denning D.W. Groll A.H. Lagrou K. Lass-Flörl C. Lewis R.E. Munoz P. Verweij P.E. Warris A. Ader F. Akova M. Arendrup M.C. Barnes R.A. Beigelman-Aubry C. Blot S. Bouza E. Brüggemann R.J.M. Buchheidt D. Cadranel J. Castagnola E. Chakrabarti A. Cuenca-Estrella M. Dimopoulos G. Fortun J. Gangneux J.P. Garbino J. Heinz W.J. Herbrecht R. Heussel C.P. Kibbler C.C. Klimko N. Kullberg B.J. Lange C. Lehrnbecher T. Löffler J. Lortholary O. Maertens J. Marchetti O. Meis J.F. Pagano L. Ribaud P. Richardson M. Roilides E. Ruhnke M. Sanguinetti M. Sheppard D.C. Sinkó J. Skiada A. Vehreschild M.J.G.T. Viscoli C. Cornely O.A. Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018 24 Suppl. 1 e1 e38 10.1016/j.cmi.2018.01.002 29544767
    [Google Scholar]
  21. de Heer K. Gerritsen M.G. Visser C.E. Leeflang M.M.G. Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients. Cochrane Libr 2019 2020 4 CD012399 10.1002/14651858.CD012399.pub2 31107543
    [Google Scholar]
  22. Koo S. Bryar J.M. Baden L.R. Marty F.M. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol 2010 48 4 1255 1260 10.1128/JCM.02281‑09 20147646
    [Google Scholar]
  23. Ulusakarya A. Chachaty E. Vantelon J-M. Youssef A. Tancrède C. Pico J-L. Bourhis J-H. Fenaux P. Munck J-N. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol J 2000 1 2 111 116 10.1038/sj.thj.6200009 11920178
    [Google Scholar]
  24. Maertens J. Verhaegen J. Lagrou K. Van Eldere J. Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: A prospective validation. Blood 2001 97 6 1604 1610 10.1182/blood.V97.6.1604 11238098
    [Google Scholar]
  25. Thornton C.R. Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol 2008 15 7 1095 1105 10.1128/CVI.00068‑08 18463222
    [Google Scholar]
/content/journals/crmr/10.2174/011573398X390376251016161929
Loading
Diagnostic Value of Galactomannan Enzyme Immunoassay Compared to Conventional Modalities in Bronchoalveolar Lavage of Immunocompromised Patients
Bentham Science Publishers ; https://doi.org/10.2174/011573398X390376251016161929
/content/journals/crmr/10.2174/011573398X390376251016161929
/content/journals/crmr/10.2174/011573398X390376251016161929
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: Galactomannan ; gram staining ; bronchoalveolar lavage ; immunocompromised, invasive aspergillosis ; KOH mount

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test